Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
| Therapy Name | BSI-082 |
| Synonyms | |
| Therapy Description |
BSI-082 is a monoclonal antibody targeting SIRPalpha, which inhibits SIRPalpha/CD47-mediated signaling, potentially decreasing tumor cell immune evasion (Cancer Res (2022) 82 (12_Supplement): 5312). |
| Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
|---|---|---|---|---|
| BSI-082 | BSI082|BSI 082 | SIRPA Antibody 9 | BSI-082 is a monoclonal antibody targeting SIRPalpha, which inhibits SIRPalpha/CD47-mediated signaling, potentially decreasing tumor cell immune evasion (Cancer Res (2022) 82 (12_Supplement): 5312). |
| Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
|---|
| Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
|---|